Mounjaro and Zepbound sales disappoint, and Eli Lilly's stock is dropping
Portfolio Pulse from
Eli Lilly's stock is experiencing a significant drop due to disappointing sales of its diabetes and obesity drugs, Mounjaro and Zepbound. This marks the worst day for the stock in four years.
January 14, 2025 | 3:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Eli Lilly's stock is dropping significantly due to underwhelming sales of its diabetes and obesity drugs, Mounjaro and Zepbound. This is the worst performance for the stock in four years.
The disappointing sales figures for Mounjaro and Zepbound directly impact Eli Lilly's revenue expectations, leading to a significant drop in stock price. The market reaction is strong due to the importance of these drugs in Eli Lilly's portfolio.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100